This report provides a new reference for understanding <i>MET</i> abnormalities in gastric cancer and offers a possibility for future application of MET tyrosine kinase inhibitors in the therapy of gastric cancer with <i>MET</i> abnormalities. This evidence concerns the gene MET and gastric cancer.